ciprofloxacin has been researched along with Sepsis in 184 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
Excerpt | Relevance | Reference |
---|---|---|
"To evaluate whether 1 week of ciprofloxacin before percutaneous nephrolithotomy (PCNL) in patients with stones of > or = 20 mm or pelvicalyceal dilatation, reduces urosepsis, as we previously reported that such patients have four times the risk of urosepsis after PCNL." | 9.12 | One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. ( Mariappan, P; Moussa, SA; Smith, G; Tolley, DA, 2006) |
"In the present study the effect of ciprofloxacin versus ceftazidime on concentrations of pro- and anti-inflammatory cytokines in the sera of patients with severe sepsis was evaluated." | 9.11 | Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria. ( Bassaris, HP; Drosou, E; Gogos, CA; Lekkou, A; Marangos, MN; Skoutelis, A; Starakis, I, 2004) |
"To compare meropenem with ciprofloxacin for treatment of gram-negative bacilli sepsis in penicillin-allergic patients in the intensive care unit (ICU) to determine if increased anaphylaxis risk with meropenem precluded its use when weighed against risks of inactive therapy with ciprofloxacin." | 8.87 | Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model. ( Bolon, MK; Esterly, JS; Lee, TA; Postelnick, M; Reddy, P; Scheetz, MH, 2011) |
"After appendectomy due to complicated acute appendicitis (CAA), there are some alternatives as antibiotic scheme: ciprofloxacin/metronidazole; as well as monoscheme based on carbapenems: ertapenem, meropenem, and imipenem." | 7.96 | Carbapenems versus ciprofloxacin/metronidazole for decreasing complications and hospital stay following complicated acute appendicitis surgery: A prospective cohort in an Ecuadorian population. ( Arevalo-Vidal, E; Baquerizo-Burgos, J; Bunces-Orellana, O; Bustos-Galarza, K; Ferrín-Viteri, M; Oleas, R; Puga-Tejada, M, 2020) |
"In this prospective audit, patients were identified as having a low- or high-risk of sepsis based on a questionnaire about established risk factors: previous biopsy; recurrent urine infections; receiving ciprofloxacin in the 12 months prior; travel to South-East Asia or South America in the previous 6 months; or diabetes, immune system impairment or receipt of immunosuppressant drugs." | 7.80 | Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate. ( Blackmore, T; Losco, G; Studd, R, 2014) |
"A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 7.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
"Fourteen patients (6 women, 8 men) with thoracolumbar spondylitis were treated with anterior surgery with insertion of titanium mesh cage and posterior instrumented fusion performed sequentially on the same day under one anesthesia." | 7.73 | Anterior surgery with insertion of titanium mesh cage and posterior instrumented fusion performed sequentially on the same day under one anesthesia for septic spondylitis of thoracolumbar spine: is the use of titanium mesh cages safe? ( Iliopoulos, P; Korovessis, P; Koureas, G; Petsinis, G; Zacharatos, S, 2006) |
"A critically ill patient with septicemic plague and peripheral gangrene was treated successfully with ciprofloxacin." | 7.72 | A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene. ( Kuberski, T; Robinson, L; Schurgin, A, 2003) |
"To determine the pharmacokinetic profile of ciprofloxacin 20 mg/kg per day (10 mg/kg administered intravenously 12 hourly) in paediatric patients with severe sepsis." | 7.71 | Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ( Gous, AG; Hon, H; Lipman, J; Mathivha, LR; Pinder, M; Riera-Fanego, JF; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2002) |
"The antibacterial activities of ciprofloxacin versus ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared." | 7.67 | Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987) |
"The antibacterial activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared." | 7.67 | Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987) |
"Hospitalized patients with sepsis caused by ciprofloxacin-susceptible organisms were treated with intravenous ciprofloxacin 300 mg every 12 hours." | 7.67 | Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin. ( Brown, AE; Smith, G, 1989) |
"In this two-centre randomised clinical trial, critically ill patients with sepsis or septic shock were randomised to AutoKinetics dosing or standard dosing for four antibiotics: vancomycin, ciprofloxacin, meropenem, and ceftriaxone." | 5.51 | Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial. ( Bosman, RJ; de Grooth, HJ; Driessen, R; Elbers, PWG; Fleuren, LM; Girbes, ARJ; Guo, T; Mathot, RAA; Roggeveen, LF; Swart, EL; Thoral, P; van den Bogaard, B; van Hest, RM, 2022) |
"Salmonellosis is a relatively rare complication in kidney transplant recipients that cannot be clinically distinguished from other forms of enteritis." | 5.46 | Severe sepsis from a Ciprofloxacin resistant salmonellosis in a kidney transplant recipient. ( Carminatti, M; Mendes, MM; Pinheiro, HS, 2017) |
" Serious adverse reactions reported with ciprofloxacin are rare with an incidence of 0." | 5.35 | Toxic epidermal necrolysis and agranulocytosis: rare adverse effects of ciprofloxacin. ( Ruxana, K; Upadya, GM, 2009) |
" Ciprofloxacin pharmacokinetics in critically ill patients do not change over time, and intra-abdominal sepsis does not alter ciprofloxacin pharmacokinetic parameters to a greater degree than sepsis from other causes in critically ill patients." | 5.33 | Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. ( Gous, A; Hon, H; Lipman, J; Mathivha, R; Pinder, M; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2005) |
" Sixteen evaluable patients (three pharmacokinetic profiles) without renal dysfunction and with severe sepsis were studied." | 5.30 | Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ( Gous, AG; Hon, H; Lipman, J; Scribante, J; Tshukutsoane, S, 1998) |
"The impact of the dosage schedule on the therapeutic efficacy of antibiotics was investigated in experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats." | 5.28 | Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, BM; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1989) |
"In this proof-of-principle intervention trial, 16 healthy young men received either no treatment or broad-spectrum antibiotics (ciprofloxacin, vancomycin and metronidazole) for 7 days, after which all were administered lipopolysaccharide intravenously to induce a transient sepsis-like syndrome." | 5.24 | Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study. ( Belzer, C; Cranendonk, DR; de Vos, AF; de Vos, WM; Lankelma, JM; van der Poll, T; Wiersinga, WJ, 2017) |
"Ciprofloxacin is a safe therapeutic option for newborns with sepsis produced by multiply resistant organisms." | 5.12 | Ciprofloxacin treatment in preterm neonates in Bangladesh: lack of effects on growth and development. ( Ahmed, AS; Bhattacharya, M; Chowdhury, MA; Darmstadt, GL; Islam, M; Khan, NZ; Law, P; Muslima, H; Saha, SK, 2006) |
"To evaluate whether 1 week of ciprofloxacin before percutaneous nephrolithotomy (PCNL) in patients with stones of > or = 20 mm or pelvicalyceal dilatation, reduces urosepsis, as we previously reported that such patients have four times the risk of urosepsis after PCNL." | 5.12 | One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. ( Mariappan, P; Moussa, SA; Smith, G; Tolley, DA, 2006) |
"In the present study the effect of ciprofloxacin versus ceftazidime on concentrations of pro- and anti-inflammatory cytokines in the sera of patients with severe sepsis was evaluated." | 5.11 | Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria. ( Bassaris, HP; Drosou, E; Gogos, CA; Lekkou, A; Marangos, MN; Skoutelis, A; Starakis, I, 2004) |
"To compare meropenem with ciprofloxacin for treatment of gram-negative bacilli sepsis in penicillin-allergic patients in the intensive care unit (ICU) to determine if increased anaphylaxis risk with meropenem precluded its use when weighed against risks of inactive therapy with ciprofloxacin." | 4.87 | Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model. ( Bolon, MK; Esterly, JS; Lee, TA; Postelnick, M; Reddy, P; Scheetz, MH, 2011) |
"Rectal swab cultures identify patients with ciprofloxacin-resistant rectal flora who have an eight-fold risk of sepsis." | 3.96 | Effect of Augmented Antimicrobial Prophylaxis and Rectal Swab Culture-guided Targeted Prophylaxis on the Risk of Sepsis Following Transrectal Prostate Biopsy. ( Dall'Antonia, M; Eragat, M; Hadjipavlou, M; Hammadeh, MY; Kenny, C; Mulhem, W; Pantelidou, M; Wood, C, 2020) |
"After appendectomy due to complicated acute appendicitis (CAA), there are some alternatives as antibiotic scheme: ciprofloxacin/metronidazole; as well as monoscheme based on carbapenems: ertapenem, meropenem, and imipenem." | 3.96 | Carbapenems versus ciprofloxacin/metronidazole for decreasing complications and hospital stay following complicated acute appendicitis surgery: A prospective cohort in an Ecuadorian population. ( Arevalo-Vidal, E; Baquerizo-Burgos, J; Bunces-Orellana, O; Bustos-Galarza, K; Ferrín-Viteri, M; Oleas, R; Puga-Tejada, M, 2020) |
"There was a significant reduction in the incidence of sepsis after prostate biopsy using a combination of a ciprofloxacin-ceftriaxone antibiotic regimen and isopropyl alcohol needle washing." | 3.88 | Reduced Risk of Sepsis after Prostate Biopsy Using a Cephalosporin-Fluoroquinolone Antibiotic Regimen and Isopropyl Alcohol Needle Washing. ( Johnson-Mitchell, M; Neeb, AD; Simmons, MN, 2018) |
" coli urosepsis was treated with ciprofloxacin for 2 weeks with excellent response." | 3.88 | IgA-dominant extracapillary proliferative glomerulonephritis following Escherichia coli sepsis in a renal transplant recipient. ( Basic-Jukic, N; Coric, M; Kastelan, Z, 2018) |
"In this prospective audit, patients were identified as having a low- or high-risk of sepsis based on a questionnaire about established risk factors: previous biopsy; recurrent urine infections; receiving ciprofloxacin in the 12 months prior; travel to South-East Asia or South America in the previous 6 months; or diabetes, immune system impairment or receipt of immunosuppressant drugs." | 3.80 | Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate. ( Blackmore, T; Losco, G; Studd, R, 2014) |
"To describe the use of ciprofloxacin and fluconazole for the treatment of sepsis in European neonatal intensive care units (NICUs) in order to better orient research aimed at acquiring essential knowledge in this critical area." | 3.79 | Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections. ( Bonati, M; Choonara, I; Jacqz-Aigrain, E; Kaguelidou, F; Manzoni, P; Pandolfini, C; Sequi, M; Turner, MA, 2013) |
"A ciprofloxacin (CFn)-loaded lipid emulsion was developed for treatment of intra-abdominal infections, especially sepsis." | 3.77 | An investigation on the approach to target lipopolysaccharide through polymeric capped nano-structured formulation for the management of sepsis. ( Mishra, PR, 2011) |
"Fourteen patients (6 women, 8 men) with thoracolumbar spondylitis were treated with anterior surgery with insertion of titanium mesh cage and posterior instrumented fusion performed sequentially on the same day under one anesthesia." | 3.73 | Anterior surgery with insertion of titanium mesh cage and posterior instrumented fusion performed sequentially on the same day under one anesthesia for septic spondylitis of thoracolumbar spine: is the use of titanium mesh cages safe? ( Iliopoulos, P; Korovessis, P; Koureas, G; Petsinis, G; Zacharatos, S, 2006) |
"A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 3.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
"24 preterm neonates with age < 28 days, who received intravenous ciprofloxacin 10 mg/kg/dose 12 hourly for clinical and/or culture proven sepsis, were enrolled." | 3.72 | Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. ( Aggarwal, P; Dutta, S; Garg, SK; Narang, A, 2004) |
"A critically ill patient with septicemic plague and peripheral gangrene was treated successfully with ciprofloxacin." | 3.72 | A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene. ( Kuberski, T; Robinson, L; Schurgin, A, 2003) |
" We isolated a strain of S choleraesuis that was resistant to ceftriaxone and ciprofloxacin from a patient with sepsis." | 3.72 | Isolation of Salmonella enterica serotype choleraesuis resistant to ceftriaxone and ciprofloxacin. ( Chia, JH; Chiu, CH; Chu, C; Lee, YS; Lin, TY; Ou, JT; Su, LH; Wu, TL, 2004) |
"In a previous study in experimental Klebsiella pneumoniae pneumonia, the therapeutic potential of ciprofloxacin was significantly improved by encapsulation in polyethylene glycol-coated ("pegylated") long-circulating (STEALTH) liposomes." | 3.71 | Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. ( Bakker-Woudenberg, IA; Guo, L; Mouton, JW; ten Kate, MT; Working, P, 2002) |
"To determine the pharmacokinetic profile of ciprofloxacin 20 mg/kg per day (10 mg/kg administered intravenously 12 hourly) in paediatric patients with severe sepsis." | 3.71 | Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ( Gous, AG; Hon, H; Lipman, J; Mathivha, LR; Pinder, M; Riera-Fanego, JF; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2002) |
"Hospitalized patients with sepsis caused by ciprofloxacin-susceptible organisms were treated with intravenous ciprofloxacin 300 mg every 12 hours." | 3.67 | Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin. ( Brown, AE; Smith, G, 1989) |
"The antibacterial activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared." | 3.67 | Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987) |
"The antibacterial activities of ciprofloxacin versus ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared." | 3.67 | Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987) |
"Twenty-four episodes of fever in neutropenic patients with haematological malignancy were treated with ciprofloxacin." | 3.67 | Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. ( Farrell, ID; Geddes, AM; Leyland, MJ; Smith, GM, 1986) |
"A steady increase in the incidence of septicemia after prostate biopsy in our unit between 2001 and 2005 prompted us to review our prophylactic antibiotic regimen." | 2.78 | Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate. ( Al-Maghrebi, M; Anim, JT; Kehinde, EO; Sheikh, M, 2013) |
"Oral ciprofloxacin is a cost-effective prophylactic agent for high-risk ERCP." | 2.69 | Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephazolin in the prophylaxis of high-risk patients. ( Alveyn, CG; Davis, AJ; Kolios, G; Robertson, DA, 1998) |
"Ora; ciprofloxacin was studied as a prophylactic antimicrobial agent in high- and low-risk patients undergoing endoscopic retrograde cholangiography." | 2.67 | Prevention of sepsis following endoscopic retrograde cholangiopancreatography. ( Alveyn, CG; Lowes, JA; Robertson, DA; Tillotson, G; Wright, R, 1991) |
"Ciprofloxacin serum levels were measured after administration of the drug to 36 patients with septicemia (at least one positive blood culture) who were able to take oral medication." | 2.66 | Serum levels of ciprofloxacin after single oral doses in patients with septicemia. ( Auckenthaler, R; Bellido, F; D'Espine, M; Hirschel, B; Lew, D; Pechère, JC; Rohner, P, 1989) |
"Ciprofloxacin displays largely concentration-dependent kill characteristics, but also exerts some time-dependent effects." | 2.43 | Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. ( Lipman, J; Roberts, JA, 2006) |
"Population-based data are needed to inform the safe prescribing of fluoroquinolone antibiotics to patients with advanced chronic kidney disease (CKD)." | 1.72 | Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease. ( Ahmadi, F; Garg, AX; Kim, RB; Knoll, GA; Muanda, FT; Silverman, MS; Sontrop, JM; Sood, MM; Weir, MA; Yoo, E, 2022) |
"sepsis is defined as a systemic inflammatory host response syndrome (SIRS) to infection, commonly bacterial." | 1.72 | Aetiology, antimicrobial susceptibility and outcome of children with sepsis, admitted at Muhimbili National Hospital, Dar es Salaam. ( Assenga, EN; Godfrey, E; Majaliwa, E, 2022) |
"Ciprofloxacin was the most prescribed oral antibiotic (53%)." | 1.72 | Intravenous to oral transition of antibiotics for gram-negative bloodstream infection at a University hospital in Thailand: Clinical outcomes and predictors of treatment failure. ( Gross, AE; Nakaranurack, C; Pradubkham, T; Suwanpimolkul, G, 2022) |
"Bacteremia-induced sepsis is a leading cause of mortality in intensive care units." | 1.62 | Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice. ( Alalaiwe, A; Dai, YS; Fang, JY; Liao, CC; Liu, FC; Yang, SC; Yu, HP, 2021) |
"Post-URS sepsis was 7." | 1.56 | Tailoring Antibiotic Prophylaxis for Ureteroscopic Procedures Based on Local Resistance Profiles May Lead to Reduced Rates of Infections and Urosepsis. ( Amiel, GE; Badaan, S; Kastin, A; Kravtsov, A; Mullerad, M; Zisman, A, 2020) |
"vulnificus septicemia during the study, and the 30-day survival rate was 39% (85/218)." | 1.51 | Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis. ( Darboe, KS; Jang, HC; Jung, SI; Kang, SJ; Kim, SE; Kim, UJ; Oh, TH; Park, KH; Shin, HY; Shin, SU, 2019) |
"Sepsis is a life-threatening disease resulted from a dysregulated host immune response to bacterial infections, continuing to cause high morbidity and mortality worldwide." | 1.48 | Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management. ( Gao, J; Wang, Z; Zhang, CY, 2018) |
"Salmonellosis is a relatively rare complication in kidney transplant recipients that cannot be clinically distinguished from other forms of enteritis." | 1.46 | Severe sepsis from a Ciprofloxacin resistant salmonellosis in a kidney transplant recipient. ( Carminatti, M; Mendes, MM; Pinheiro, HS, 2017) |
"The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo." | 1.43 | Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. ( Díaz-De-Alba, P; Docobo-Perez, F; Machuca, J; Ortiz, M; Pascual, Á; Recacha, E; Rodríguez-Martínez, JM, 2016) |
"Ciprofloxacin resistance was found in 90." | 1.43 | The prevalence of urinary tract infection, or urosepsis following transrectal ultrasound-guided prostate biopsy in a subset of the Saudi population and patterns of susceptibility to flouroquinolones. ( Albqami, NM; AlKhateeb, SS; Alrabeeah, KA; AlShammari, NA; AlZughaibi, MA; Ghazwani, YG, 2016) |
" Population pharmacokinetic analysis and Monte Carlo simulation was undertaken using Pmetrics." | 1.43 | Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ( Lefrant, JY; Lipman, J; Louart, B; Muller, L; Roberts, JA; Roger, C; Wallis, SC, 2016) |
"Anthrax is a zoonotic occupational disease caused by Bacillus anthracis, a rod-shaped immobile aerobic gram-positive bacteria with spore." | 1.43 | A case report of inhalation anthrax acquired naturally. ( Azarkar, Z; Bidaki, MZ, 2016) |
"Ciprofloxacin alone was associated with significantly more infections than ciprofloxacin plus an additional agent (P = 0." | 1.42 | Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy. ( Gupta, K; Lerner, L; Marino, K; Orlando, R; Parlee, A; Strymish, J, 2015) |
"We report a case of C." | 1.42 | Successful Treatment of Chromobacterium violaceum Sepsis in a South Indian Adult. ( Madi, DR; Ramapuram, J; Shetty, AK; Vidyalakshmi, K, 2015) |
"chelonae may be associated with nosocomial infections including catheter related sepsis, pneumonia etc." | 1.42 | Catheter related line sepsis resulting from Mycobacterium chelonae infection in an immunocompromised host. ( Antony, SJ, 2015) |
"Prostate cancer is the most common form of cancer in Danish men, and the incidence is rising." | 1.40 | Prophylactic antibiotics reduce sepsis after biopsy of the prostate. ( Hayatzaki, K; Menne, S; Nielsen, K, 2014) |
"Methicillin resistance was seen in 10/46 (21." | 1.39 | Bloodstream infection among adults in Phnom Penh, Cambodia: key pathogens and resistance patterns. ( De Smet, B; Jacobs, JA; Kham, C; Koole, O; Lim, K; Lynen, L; Peetermans, WE; Phe, T; Veng, HC; Vlieghe, ER, 2013) |
"We report a case of bacteremia and severe sepsis caused by S." | 1.36 | Mycotic abdominal aortic aneurysm due to Streptococcus suis: a case report. ( Arworn, S; Laohapensang, K; Rutherford, RB, 2010) |
" Serious adverse reactions reported with ciprofloxacin are rare with an incidence of 0." | 1.35 | Toxic epidermal necrolysis and agranulocytosis: rare adverse effects of ciprofloxacin. ( Ruxana, K; Upadya, GM, 2009) |
"Ciprofloxacin-untreated rats exhibited a predominantly gram-negative polymicrobial sepsis." | 1.34 | Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. ( Fareed, J; Florian-Kujawski, M; Goto, M; Hammadeh, R; Hoppensteadt, D; Iqbal, O; Ravindranath, TM; Sayeed, MM, 2007) |
" Ciprofloxacin pharmacokinetics in critically ill patients do not change over time, and intra-abdominal sepsis does not alter ciprofloxacin pharmacokinetic parameters to a greater degree than sepsis from other causes in critically ill patients." | 1.33 | Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. ( Gous, A; Hon, H; Lipman, J; Mathivha, R; Pinder, M; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2005) |
"The majority of data evaluating Salmonella infections in sickle cell anemia (SCD) comes from studies performed in children." | 1.33 | Ceftriaxone-resistant Salmonella septicemia and osteomyelitis in sickle cell disease adults. ( Laber, DA; Morgan, JS, 2006) |
"We conducted a case matched control study to observe the adverse effects of ciprofloxacin used in neonatal septicemia We enrolled 30 neonates with multidrug-resistant septicemia who were treated with intravenous ciprofloxacin for 14 days." | 1.32 | Safety profile of ciprofloxacin used for neonatal septicemia. ( Ambardekar, S; Chaudhari, S; Chinchwadkar, M; Kinare, A; Suryawanshi, P, 2004) |
"Sepsis was induced by cecal ligation and puncture (CLP) in Swiss mice using an 18-gauge needle." | 1.32 | Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. ( Amâncio, RT; Bozza, FA; Bozza, PT; Castro-Faria-Neto, HC; David, CM; Gomes, RN; Vianna, RC, 2004) |
"Treatment with ciprofloxacin and gamma-globulin dramatically improved the patient's clinical features." | 1.32 | [Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient]. ( Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M, 2004) |
" Sixteen evaluable patients (three pharmacokinetic profiles) without renal dysfunction and with severe sepsis were studied." | 1.30 | Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ( Gous, AG; Hon, H; Lipman, J; Scribante, J; Tshukutsoane, S, 1998) |
"Ciprofloxacin has been found to be effective in the treatment of multidrug-resistant Gram-negative infections in pediatric patients, including premature infants." | 1.30 | Successful treatment of late-onset infection due to resistant Klebsiella pneumoniae in an extremely low birth weight infant using ciprofloxacin. ( Khaneja, M; Kumar, A; Naprawa, J; Piecuch, S, 1999) |
"A case of typhoid fever caused by a multiply antibiotic resistant strain of Salmonella typhi is reported." | 1.28 | Septicaemia caused by an imported strain of multiply antibiotic resistant Salmonella typhi successfully treated with ciprofloxacin. ( Bhana, R; Coovadia, Y; Seebaran, A, 1990) |
"Ciprofloxacin was slightly more potent than sparfloxacin against Serratia marcescens (n = 14), the MIC90 values being 0." | 1.28 | Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. ( Bale, MJ; Doebbeling, BN; Pfaller, MA; Wenzel, RP, 1990) |
"Amikacin was bacteriostatic, with an MIC of 4." | 1.28 | Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice. ( Inderlied, CB; Kolonoski, PT; Wu, M; Young, LS, 1989) |
"A case of septicemia caused by MRSA is reported with discussion on its prophylaxis." | 1.28 | [A case report of septicemia caused by methicillin cephem resistant Staphylococcus aureus (MRSA)]. ( Arakawa, S; Den, S; Gohji, K; Ka, S; Kamidono, S; Maeda, H; Matsui, T; Matsumoto, O; Okada, H; Takagi, S, 1989) |
"In ciprofloxacin-treated patients the flora were almost completely ciprofloxacin-resistant, whereas in the control groups resistant flora were detected only occasionally." | 1.28 | Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. ( Huovinen, P; Kotilainen, P; Nikoskelainen, J, 1990) |
"Ciprofloxacin was withdrawn from use in the unit and daily bathing with chlorhexidine gluconate solution started." | 1.28 | Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. ( Burnie, JP; Hartley, JW; Lee, W; Oppenheim, BA, 1989) |
"The impact of the dosage schedule on the therapeutic efficacy of antibiotics was investigated in experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats." | 1.28 | Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, BM; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1989) |
"Ciprofloxacin treatment was effective on both occasions." | 1.28 | Successful treatment of Bacillus cereus infection with ciprofloxacin. ( Gascoigne, AD; Gibson, GJ; Gould, K; Richards, J, 1991) |
"Treatment with ofloxacin and ciprofloxacin at 50 mg/kg 18 h after infection did not significantly increase survival rates compared with those of untreated controls." | 1.28 | Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. ( Azoulay-Dupuis, E; Bedos, JP; Hardy, DJ; Pocidalo, JJ; Swanson, RN; Vallée, E, 1991) |
"Ciprofloxacin is an effective and safe therapeutic alternative in many tissue infections caused by susceptible microorganisms." | 1.27 | Open, prospective study of the clinical efficacy of ciprofloxacin. ( Bran, JL; Garcia, JF; Mejia, CR; Ramirez, CA, 1985) |
" This finding was likely due to changes in the pharmacokinetics of the drug with multiple dosing and in infected versus uninfected rabbits." | 1.27 | Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. ( Barriere, SL; Fekety, R; Kaatz, GW; Schaberg, DR, 1987) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 34 (18.48) | 18.7374 |
1990's | 26 (14.13) | 18.2507 |
2000's | 37 (20.11) | 29.6817 |
2010's | 67 (36.41) | 24.3611 |
2020's | 20 (10.87) | 2.80 |
Authors | Studies |
---|---|
Cecchetti, V | 1 |
Fravolini, A | 1 |
Lorenzini, MC | 1 |
Tabarrini, O | 1 |
Terni, P | 1 |
Xin, T | 1 |
Gerasyuto, AI | 1 |
Arnold, MA | 1 |
Wang, J | 1 |
Chen, G | 1 |
Zhang, X | 1 |
Smith, S | 1 |
Woll, MG | 1 |
Baird, J | 1 |
Zhang, N | 1 |
Almstead, NG | 1 |
Narasimhan, J | 1 |
Peddi, S | 1 |
Dumble, M | 1 |
Sheedy, J | 1 |
Weetall, M | 1 |
Branstrom, AA | 1 |
Prasad, JVN | 1 |
Karp, GM | 1 |
Mohammed, JM | 1 |
Sajana, TM | 1 |
Raj, R | 1 |
Rachana, BA | 1 |
Paul, G | 1 |
Pillai, PR | 1 |
Rodríguez, I | 1 |
Figueiredo, AS | 1 |
Sousa, M | 1 |
Aracil-Gisbert, S | 1 |
Fernández-de-Bobadilla, MD | 1 |
Lanza, VF | 1 |
Rodríguez, C | 1 |
Zamora, J | 1 |
Loza, E | 1 |
Mingo, P | 1 |
Brooks, CJ | 1 |
Cantón, R | 1 |
Baquero, F | 1 |
Coque, TM | 1 |
Coombs, GW | 1 |
Daley, DA | 1 |
Yee, NWT | 1 |
Shoby, P | 1 |
Mowlaboccus, S | 1 |
Al-Faifi, J | 1 |
Ibrahim, ME | 1 |
Muanda, FT | 1 |
Sood, MM | 1 |
Weir, MA | 1 |
Sontrop, JM | 1 |
Ahmadi, F | 1 |
Yoo, E | 1 |
Kim, RB | 1 |
Silverman, MS | 1 |
Knoll, GA | 1 |
Garg, AX | 1 |
Roggeveen, LF | 1 |
Guo, T | 1 |
Fleuren, LM | 1 |
Driessen, R | 1 |
Thoral, P | 1 |
van Hest, RM | 1 |
Mathot, RAA | 1 |
Swart, EL | 1 |
de Grooth, HJ | 1 |
van den Bogaard, B | 1 |
Girbes, ARJ | 1 |
Bosman, RJ | 1 |
Elbers, PWG | 1 |
Pradubkham, T | 1 |
Suwanpimolkul, G | 1 |
Gross, AE | 1 |
Nakaranurack, C | 1 |
Godfrey, E | 1 |
Majaliwa, E | 1 |
Assenga, EN | 1 |
Tian, C | 1 |
Xing, M | 1 |
Zhao, Y | 1 |
Fan, X | 1 |
Bai, Y | 1 |
Fu, L | 1 |
Wang, S | 1 |
Wang, DY | 1 |
Yang, G | 1 |
Zhang, XX | 1 |
van der Mei, HC | 1 |
Ren, Y | 1 |
Busscher, HJ | 1 |
Shi, L | 1 |
Nielsen, RT | 1 |
Andersen, CØ | 1 |
Schønheyder, HC | 1 |
Petersen, JH | 1 |
Knudsen, JD | 1 |
Jarløv, JO | 1 |
Norredam, M | 1 |
Islam, MA | 1 |
Alam, SM | 1 |
Reza, AM | 1 |
Atassi, G | 1 |
Medernach, R | 1 |
Scheetz, M | 1 |
Nozick, S | 1 |
Rhodes, NJ | 1 |
Murphy-Belcaster, M | 1 |
Murphy, KR | 1 |
Alisoltani, A | 1 |
Ozer, EA | 1 |
Hauser, AR | 1 |
Zisman, A | 1 |
Badaan, S | 1 |
Kastin, A | 1 |
Kravtsov, A | 1 |
Amiel, GE | 1 |
Mullerad, M | 1 |
Wolf, S | 1 |
Frosch, T | 2 |
Popp, J | 1 |
Pletz, MW | 1 |
Hadjipavlou, M | 1 |
Eragat, M | 1 |
Kenny, C | 1 |
Pantelidou, M | 1 |
Mulhem, W | 1 |
Wood, C | 1 |
Dall'Antonia, M | 1 |
Hammadeh, MY | 1 |
Forde, C | 1 |
McMullan, R | 1 |
Clarke, M | 1 |
Wilson, RH | 1 |
Plummer, R | 1 |
Grayson, M | 1 |
McDowell, C | 1 |
Agus, A | 1 |
Doran, A | 1 |
McAuley, DF | 1 |
Thomas, AL | 1 |
Barnes, RA | 1 |
Adams, R | 1 |
Chau, I | 1 |
Coyle, V | 1 |
Bunces-Orellana, O | 1 |
Arevalo-Vidal, E | 1 |
Bustos-Galarza, K | 1 |
Ferrín-Viteri, M | 1 |
Oleas, R | 1 |
Baquerizo-Burgos, J | 1 |
Puga-Tejada, M | 1 |
Mazumder, R | 1 |
Sadique, T | 1 |
Sen, D | 1 |
Mozumder, P | 1 |
Rahman, T | 1 |
Chowdhury, A | 1 |
Halim, F | 1 |
Akter, N | 1 |
Ahmed, D | 1 |
Barnawi, AI | 1 |
Kordy, FN | 1 |
Almuwallad, OK | 1 |
Kassarah, KA | 1 |
Liao, CC | 1 |
Yu, HP | 1 |
Yang, SC | 1 |
Alalaiwe, A | 1 |
Dai, YS | 1 |
Liu, FC | 1 |
Fang, JY | 1 |
Mendes, MM | 1 |
Carminatti, M | 1 |
Pinheiro, HS | 1 |
Zembower, TR | 1 |
Maxwell, KM | 1 |
Nadler, RB | 1 |
Cashy, J | 1 |
Scheetz, MH | 2 |
Qi, C | 1 |
Schaeffer, AJ | 1 |
Goodlet, KJ | 1 |
Nicolau, DP | 1 |
Nailor, MD | 1 |
Rossi, O | 1 |
Dybowski, R | 1 |
Maskell, DJ | 1 |
Grant, AJ | 1 |
Restif, O | 1 |
Mastroeni, P | 1 |
Trinh, SA | 1 |
Gavin, HE | 1 |
Satchell, KJF | 1 |
Bloomfield, M | 1 |
Blackmore, T | 2 |
Qi, DZ | 1 |
Lehman, K | 1 |
Dewan, K | 2 |
Kirimanjeswara, G | 2 |
Raman, JD | 3 |
Roberts, MJ | 1 |
Scott, S | 1 |
Harris, PN | 1 |
Naber, K | 1 |
Wagenlehner, FME | 1 |
Doi, SAR | 1 |
Simmons, MN | 1 |
Neeb, AD | 1 |
Johnson-Mitchell, M | 1 |
Atala, A | 2 |
Elshal, AM | 1 |
Atwa, AM | 1 |
El-Nahas, AR | 1 |
El-Ghar, MA | 1 |
Gaber, A | 1 |
Elsawy, E | 1 |
Hashem, A | 1 |
Farag, Y | 1 |
Farg, H | 1 |
Elsorougy, A | 1 |
Fouda, M | 1 |
Nabeeh, H | 1 |
Mosbah, A | 1 |
Basic-Jukic, N | 1 |
Coric, M | 1 |
Kastelan, Z | 1 |
Zhang, CY | 1 |
Gao, J | 1 |
Wang, Z | 1 |
Fadel, MG | 1 |
Louis, C | 1 |
Tay, A | 1 |
Bolgeri, M | 1 |
Sewell, J | 1 |
Chow, K | 1 |
De Sousa, A | 1 |
Sapre, N | 1 |
Norris, B | 1 |
Namdarian, B | 1 |
Sinickas, V | 1 |
Huang, JG | 1 |
Anderson, P | 1 |
Kim, SE | 3 |
Shin, SU | 1 |
Oh, TH | 1 |
Kim, UJ | 2 |
Darboe, KS | 2 |
Kang, SJ | 3 |
Jang, HC | 3 |
Jung, SI | 3 |
Shin, HY | 1 |
Park, KH | 4 |
Kim, HK | 2 |
Choi, SM | 2 |
Yu, Y | 1 |
Kang, G | 1 |
Kim, YR | 2 |
Rhee, JH | 2 |
Lipton, G | 1 |
Tikka, T | 1 |
Soulsby, H | 1 |
Keh, S | 1 |
Vlieghe, ER | 1 |
Phe, T | 1 |
De Smet, B | 1 |
Veng, HC | 1 |
Kham, C | 1 |
Lim, K | 1 |
Koole, O | 1 |
Lynen, L | 1 |
Peetermans, WE | 1 |
Jacobs, JA | 1 |
Gaylis, F | 1 |
Fink, L | 1 |
Eshwara, VK | 1 |
Sasi, A | 1 |
Munim, F | 1 |
Purkayastha, J | 1 |
Lewis, LE | 1 |
Mukhopadhyay, C | 1 |
Ozgur, BC | 1 |
Sarici, H | 1 |
Doluoglu, OG | 1 |
Telli, O | 1 |
Eroglu, M | 1 |
Yeh, TC | 1 |
Liu, HC | 1 |
Hou, JY | 1 |
Chen, KH | 1 |
Huang, TH | 1 |
Chang, CY | 1 |
Liang, DC | 1 |
Jain, V | 1 |
Shukla, P | 1 |
Pal, R | 1 |
Mishra, PR | 2 |
Losco, G | 1 |
Studd, R | 1 |
Ryu, PY | 1 |
Lee, TH | 1 |
Choy, HE | 1 |
Hanna, MY | 1 |
Tremlett, C | 1 |
Josan, G | 1 |
Eltom, A | 1 |
Mills, R | 1 |
Rochester, M | 1 |
Livermore, DM | 1 |
Heidari Bateni, Z | 1 |
Shahrokh, H | 1 |
Salimi, H | 1 |
Safari, H | 1 |
Tabatabai, M | 1 |
Saedi, D | 1 |
Hayatzaki, K | 1 |
Menne, S | 1 |
Nielsen, K | 1 |
Rossmann, FS | 1 |
Racek, T | 1 |
Wobser, D | 1 |
Puchalka, J | 1 |
Rabener, EM | 1 |
Reiger, M | 1 |
Hendrickx, AP | 1 |
Diederich, AK | 1 |
Jung, K | 1 |
Klein, C | 1 |
Huebner, J | 1 |
Liss, MA | 1 |
Kim, W | 1 |
Moskowitz, D | 1 |
Szabo, RJ | 1 |
Antony, SJ | 1 |
Madi, DR | 1 |
Vidyalakshmi, K | 1 |
Ramapuram, J | 1 |
Shetty, AK | 1 |
Marino, K | 1 |
Parlee, A | 1 |
Orlando, R | 2 |
Lerner, L | 1 |
Strymish, J | 1 |
Gupta, K | 1 |
Wagenlehner, F | 1 |
Lehman, KK | 1 |
Ahn, JY | 1 |
Min, JK | 1 |
Kim, MH | 1 |
Moon, SY | 1 |
Lee, MS | 1 |
Son, JS | 1 |
Azarkar, Z | 1 |
Bidaki, MZ | 1 |
Roger, C | 1 |
Wallis, SC | 1 |
Louart, B | 1 |
Lefrant, JY | 1 |
Lipman, J | 5 |
Muller, L | 1 |
Roberts, JA | 2 |
Nazir, S | 1 |
Brown, K | 1 |
Shin, AK | 1 |
Donato, AA | 1 |
Lankelma, JM | 1 |
Cranendonk, DR | 1 |
Belzer, C | 1 |
de Vos, AF | 1 |
de Vos, WM | 1 |
van der Poll, T | 1 |
Wiersinga, WJ | 1 |
AlKhateeb, SS | 1 |
AlShammari, NA | 1 |
AlZughaibi, MA | 1 |
Ghazwani, YG | 1 |
Alrabeeah, KA | 1 |
Albqami, NM | 1 |
Machuca, J | 1 |
Ortiz, M | 1 |
Recacha, E | 1 |
Díaz-De-Alba, P | 1 |
Docobo-Perez, F | 2 |
Rodríguez-Martínez, JM | 1 |
Pascual, Á | 1 |
Kesler, KA | 1 |
Langdorf, MI | 1 |
Burns, MJ | 1 |
Vrtis, MC | 1 |
Kim, DM | 1 |
Cho, HS | 1 |
Kang, JI | 1 |
Kim, HS | 1 |
Park, CY | 1 |
Farhat, H | 1 |
Chachaty, E | 1 |
Antoun, S | 1 |
Nitenberg, G | 1 |
Zahar, JR | 1 |
Moniri, R | 1 |
Dastehgoli, K | 1 |
Laohapensang, K | 1 |
Rutherford, RB | 1 |
Arworn, S | 1 |
Upadya, GM | 1 |
Ruxana, K | 1 |
Aygencel, G | 1 |
Dizbay, M | 1 |
Loron, G | 1 |
Olivier, P | 1 |
See, H | 1 |
Le Saché, N | 1 |
Angulo, L | 1 |
Biran, V | 1 |
Brunelle, N | 1 |
Besson-Lescure, B | 1 |
Kitzis, MD | 1 |
Pansiot, J | 1 |
Bingen, E | 1 |
Gressens, P | 1 |
Bonacorsi, S | 1 |
Baud, O | 1 |
Bolon, MK | 1 |
Esterly, JS | 1 |
Reddy, P | 1 |
Postelnick, M | 1 |
Lee, TA | 1 |
Smani, Y | 1 |
López-Rojas, R | 1 |
Domínguez-Herrera, J | 1 |
Martí, S | 1 |
Vila, J | 1 |
Pachón, J | 1 |
Pinkhasov, GI | 1 |
Lin, YK | 1 |
Palmerola, R | 1 |
Smith, P | 1 |
Mahon, F | 1 |
Kaag, MG | 1 |
Dagen, JE | 1 |
Harpster, LE | 1 |
Reese, CT | 1 |
Issaoui, S | 1 |
Maoulainine, FM | 1 |
Elidrissi, NS | 1 |
Sorra, N | 1 |
Chabaa, L | 1 |
Aboussad, A | 1 |
Carignan, A | 1 |
Roussy, JF | 1 |
Lapointe, V | 1 |
Valiquette, L | 1 |
Sabbagh, R | 1 |
Pépin, J | 1 |
Marra, A | 1 |
Lamb, L | 1 |
Medina, I | 1 |
George, D | 1 |
Gibson, G | 1 |
Hardink, J | 1 |
Rugg, J | 1 |
Van Deusen, J | 1 |
O'Donnell, JP | 1 |
Kehinde, EO | 1 |
Al-Maghrebi, M | 1 |
Sheikh, M | 1 |
Anim, JT | 1 |
Pandolfini, C | 2 |
Kaguelidou, F | 1 |
Sequi, M | 1 |
Jacqz-Aigrain, E | 1 |
Choonara, I | 1 |
Turner, MA | 1 |
Manzoni, P | 1 |
Bonati, M | 1 |
Coutinho, AS | 1 |
de Morais, OO | 1 |
Gomes, CM | 1 |
de Oliveira Carneiro da Motta, J | 1 |
Gollard, R | 1 |
Rahman, S | 1 |
Ratnasabapathy, R | 1 |
Breda, SA | 1 |
Guzmán, ML | 1 |
Confalonieri, A | 1 |
González, C | 1 |
Sparo, M | 1 |
Manzo, RH | 1 |
Bruni, SS | 1 |
Olivera, ME | 1 |
Marco, S | 1 |
Paolo, M | 1 |
Maurizio, B | 1 |
Demirtas, A | 1 |
Yildirim, YE | 1 |
Sofikerim, M | 2 |
Kaya, EG | 1 |
Akinsal, EC | 1 |
Tombul, ST | 1 |
Ekmekcioglu, O | 1 |
Gulmez, I | 2 |
Bakker-Woudenberg, IA | 4 |
ten Kate, MT | 1 |
Guo, L | 1 |
Working, P | 1 |
Mouton, JW | 1 |
Rosenthal, EJ | 1 |
Kuberski, T | 1 |
Robinson, L | 1 |
Schurgin, A | 1 |
Fendukly, F | 1 |
Karlsson, I | 1 |
Hanson, HS | 1 |
Kronvall, G | 1 |
Dornbusch, K | 1 |
Bagia, JS | 1 |
Hall, R | 1 |
Vianna, RC | 1 |
Gomes, RN | 1 |
Bozza, FA | 1 |
Amâncio, RT | 1 |
Bozza, PT | 1 |
David, CM | 1 |
Castro-Faria-Neto, HC | 1 |
Chiu, CH | 1 |
Su, LH | 1 |
Chu, C | 1 |
Chia, JH | 1 |
Wu, TL | 1 |
Lin, TY | 1 |
Lee, YS | 1 |
Ou, JT | 1 |
Gogos, CA | 1 |
Skoutelis, A | 1 |
Lekkou, A | 1 |
Drosou, E | 1 |
Starakis, I | 1 |
Marangos, MN | 1 |
Bassaris, HP | 1 |
Perera, S | 1 |
Palasuntheram, C | 1 |
Aggarwal, P | 1 |
Dutta, S | 1 |
Garg, SK | 1 |
Narang, A | 1 |
Obara, Y | 1 |
Nagai, T | 1 |
Mori, M | 1 |
Ohmine, K | 1 |
Toshima, M | 1 |
Komatsu, N | 1 |
Ozawa, K | 1 |
Chaudhari, S | 1 |
Suryawanshi, P | 1 |
Ambardekar, S | 1 |
Chinchwadkar, M | 1 |
Kinare, A | 1 |
Ray, P | 1 |
Sharma, J | 1 |
Marak, RS | 1 |
Singhi, S | 1 |
Taneja, N | 1 |
Garg, RK | 1 |
Sharma, M | 1 |
Alkorta, M | 1 |
Giménez, MJ | 1 |
Vicente, D | 1 |
Aguilar, L | 1 |
Pérez-Trallero, E | 1 |
Gous, A | 1 |
Scribante, J | 3 |
Tshukutsoane, S | 3 |
Hon, H | 3 |
Pinder, M | 2 |
Mathivha, R | 1 |
Verhoef, L | 2 |
Stass, H | 2 |
Engelhardt, D | 1 |
Ruckdeschel, G | 1 |
Morris, P | 1 |
O'Sullivan, E | 1 |
Choo, M | 1 |
Barry, C | 1 |
Thompson, CJ | 1 |
Korovessis, P | 1 |
Petsinis, G | 1 |
Koureas, G | 1 |
Iliopoulos, P | 1 |
Zacharatos, S | 1 |
Morgan, JS | 1 |
Laber, DA | 1 |
Mariappan, P | 1 |
Smith, G | 2 |
Moussa, SA | 1 |
Tolley, DA | 1 |
Ahmed, AS | 1 |
Khan, NZ | 1 |
Saha, SK | 1 |
Chowdhury, MA | 1 |
Muslima, H | 1 |
Law, P | 1 |
Islam, M | 1 |
Bhattacharya, M | 1 |
Darmstadt, GL | 1 |
Karacagil, M | 1 |
Corbin, A | 1 |
Delatte, C | 1 |
Besson, S | 1 |
Guidry, A | 1 |
Hoffmann, AH | 1 |
Monier, P | 1 |
Nathaniel, R | 1 |
Ravindranath, TM | 1 |
Goto, M | 1 |
Iqbal, O | 1 |
Florian-Kujawski, M | 1 |
Hoppensteadt, D | 1 |
Hammadeh, R | 1 |
Sayeed, MM | 1 |
Fareed, J | 1 |
Begum, SA | 1 |
Lutfor, AB | 1 |
Mollah, AH | 1 |
Hasan, MK | 1 |
Ahmed, S | 1 |
Akhter, M | 1 |
Salauddin, NM | 1 |
van Hees, BC | 1 |
de Ruiter, E | 1 |
Wiltink, EH | 1 |
de Jongh, BM | 1 |
Tersmette, M | 1 |
Rossi, P | 1 |
Persson, B | 1 |
Boels, PJ | 1 |
Arner, A | 1 |
Weitzberg, E | 1 |
Oldner, A | 1 |
Klesel, N | 1 |
Geweniger, KH | 1 |
Koletzki, P | 1 |
Isert, D | 1 |
Limbert, M | 1 |
Markus, A | 1 |
Riess, G | 1 |
Schramm, H | 1 |
Iyer, P | 1 |
Burnett, RJ | 1 |
Haverstock, DC | 1 |
Dellinger, EP | 1 |
Reinhart, HH | 1 |
Bohnen, JM | 1 |
Rotstein, OD | 1 |
Vogel, SB | 1 |
Solomkin, JS | 1 |
Perras, B | 1 |
Kreft, B | 1 |
Wiedemann, G | 1 |
Bloch, KC | 1 |
Nadarajah, R | 1 |
Jacobs, R | 1 |
Galley, HF | 1 |
Nelson, SJ | 1 |
Dubbels, AM | 1 |
Webster, NR | 1 |
Mulder, JG | 1 |
Kosterink, JG | 1 |
Degener, JE | 1 |
Davis, AJ | 1 |
Kolios, G | 1 |
Alveyn, CG | 2 |
Robertson, DA | 2 |
Newcomb, D | 1 |
Bolgos, G | 1 |
Green, L | 1 |
Remick, DG | 1 |
Gous, AG | 2 |
Opal, SM | 1 |
Jhung, JW | 1 |
Keith, JC | 1 |
Palardy, JE | 1 |
Parejo, NA | 1 |
Young, LD | 1 |
Bhattacharjee, A | 1 |
Khaneja, M | 1 |
Naprawa, J | 1 |
Kumar, A | 1 |
Piecuch, S | 1 |
Gilad, J | 1 |
Borer, A | 1 |
Peled, N | 1 |
Riesenberg, K | 1 |
Tager, S | 1 |
Appelbaum, A | 1 |
Schlaeffer, F | 1 |
Moore, CC | 1 |
Lane, JE | 1 |
Stephens, JL | 1 |
Mastrullo, L | 1 |
De Blasi, D | 1 |
Boffa, ML | 1 |
Zorzato, G | 1 |
Miraglia, E | 1 |
Mathivha, LR | 1 |
Riera-Fanego, JF | 1 |
Ghadage, DP | 1 |
Bal, AM | 1 |
Nelson, MR | 1 |
Shanson, DC | 1 |
Hawkins, DA | 1 |
Gazzard, BG | 1 |
Wright, R | 1 |
Lowes, JA | 1 |
Tillotson, G | 1 |
Roach, MB | 1 |
Figueroa, TE | 1 |
McBride, D | 1 |
George, WJ | 1 |
Neal, DE | 1 |
Gascoigne, AD | 1 |
Richards, J | 1 |
Gould, K | 1 |
Gibson, GJ | 1 |
Shah, PM | 1 |
Azoulay-Dupuis, E | 1 |
Bedos, JP | 1 |
Vallée, E | 1 |
Hardy, DJ | 1 |
Swanson, RN | 1 |
Pocidalo, JJ | 1 |
Coovadia, Y | 1 |
Seebaran, A | 1 |
Bhana, R | 1 |
Oliver, RM | 1 |
Waller, DG | 1 |
Rubin, CM | 1 |
Booth, LV | 1 |
Doebbeling, BN | 1 |
Pfaller, MA | 1 |
Bale, MJ | 1 |
Wenzel, RP | 1 |
Choo, PW | 1 |
Gantz, NM | 1 |
Lode, H | 1 |
Wiley, E | 1 |
Olschewski, P | 1 |
Sievers, H | 1 |
Wintermantel, M | 1 |
Baetz, R | 1 |
Lebahn, K | 1 |
Reinke, M | 1 |
Wagner, J | 1 |
Borner, K | 1 |
Warren, RE | 1 |
Wimperis, JZ | 1 |
Baglin, TP | 1 |
Constantine, CE | 1 |
Marcus, R | 1 |
Kotilainen, P | 1 |
Nikoskelainen, J | 1 |
Huovinen, P | 1 |
Dekker, AW | 1 |
Rozenberg-Arska, M | 1 |
Verdonck, LF | 1 |
Grabe, M | 1 |
Forsgren, A | 1 |
Björk, T | 1 |
Pedro-Botet Montoya, J | 1 |
Tomás Vecina, S | 1 |
Soriano Giménez, JC | 1 |
Rubiés-Prat, J | 1 |
Oppenheim, BA | 1 |
Hartley, JW | 1 |
Lee, W | 1 |
Burnie, JP | 1 |
Díaz-Tejeiro, R | 1 |
Díez, J | 1 |
Maduell, F | 1 |
Esparza, N | 1 |
Errasti, P | 1 |
Purroy, A | 1 |
Roosendaal, R | 3 |
van den Berghe-van Raffe, M | 3 |
Vink-van den Berg, JC | 3 |
Michel, BM | 1 |
Gangji, D | 1 |
Jacobs, F | 1 |
de Jonckheer, J | 1 |
Coppens, L | 1 |
Serruys, E | 1 |
Hanotte, F | 1 |
Motte, S | 1 |
Thys, JP | 1 |
Bouza, E | 1 |
Díaz-López, MD | 1 |
Bernaldo de Quirós, JC | 1 |
Rodríguez-Créixems, M | 1 |
Greenberg, RN | 1 |
Wilson, KM | 1 |
Brusca, PA | 1 |
Brown, AE | 1 |
Bannon, MJ | 1 |
Stutchfield, PR | 1 |
Weindling, AM | 1 |
Damjanovic, V | 1 |
Weers-Pothoff, G | 1 |
Novakova, IR | 1 |
Donnelly, JP | 1 |
Muytjens, HL | 1 |
D'Espine, M | 1 |
Bellido, F | 1 |
Pechère, JC | 1 |
Auckenthaler, R | 1 |
Rohner, P | 1 |
Lew, D | 1 |
Hirschel, B | 1 |
Jacobson, MA | 1 |
Hahn, SM | 1 |
Gerberding, JL | 1 |
Lee, B | 1 |
Sande, MA | 1 |
Inderlied, CB | 1 |
Kolonoski, PT | 1 |
Wu, M | 1 |
Young, LS | 1 |
Arakawa, S | 1 |
Takagi, S | 1 |
Matsui, T | 1 |
Maeda, H | 1 |
Ka, S | 1 |
Den, S | 1 |
Gohji, K | 1 |
Okada, H | 1 |
Matsumoto, O | 1 |
Kamidono, S | 1 |
Cooper, B | 1 |
Lawlor, M | 1 |
Ramirez, CA | 1 |
Bran, JL | 1 |
Mejia, CR | 1 |
Garcia, JF | 1 |
Patton, WN | 1 |
Smith, GM | 2 |
Leyland, MJ | 2 |
Geddes, AM | 2 |
Zumla, A | 1 |
Lewis, D | 1 |
Brown, J | 1 |
Bendig, JW | 1 |
Kyle, PW | 1 |
Giangrande, PL | 1 |
Samson, DM | 1 |
Azadian, BS | 1 |
Zervos, MJ | 1 |
Bacon, AE | 1 |
Patterson, JE | 1 |
Schaberg, DR | 2 |
Kauffman, CA | 1 |
Daikos, GL | 1 |
Kathpalia, SB | 1 |
Lolans, VT | 1 |
Jackson, GG | 1 |
Fosslien, E | 1 |
Trautmann, M | 1 |
Brückner, O | 1 |
Marre, R | 1 |
Hahn, H | 1 |
Michel, MF | 2 |
Newland, AC | 1 |
Wood, ME | 1 |
Rolston, KV | 1 |
Ho, DH | 1 |
LeBlanc, B | 1 |
Bodey, GP | 1 |
Farrell, ID | 1 |
Connolly, MJ | 1 |
Snow, MH | 1 |
Ingham, HR | 1 |
Kaatz, GW | 1 |
Barriere, SL | 1 |
Fekety, R | 1 |
Dibble, JB | 1 |
Acomb, C | 1 |
Campbell, L | 1 |
White, LO | 1 |
Brownjohn, AM | 1 |
Weinstein, MP | 1 |
Masur, H | 1 |
Tuazon, C | 1 |
Gill, V | 1 |
Grimes, G | 1 |
Baird, B | 1 |
Fauci, AS | 1 |
Lane, HC | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized Controlled Trial to Investigate the Infectious Outcomes of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of Needle Tip During Transrectal Ultrasound Guided Prostate Biopsy[NCT03879486] | 1,257 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP)[NCT01659866] | Phase 4 | 563 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia[NCT02127749] | 16 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
Neutrophil and Lymphocyte Counts and the Neutrophil-to-lymphocyte Ratio as a Predictor of Fever Following Percutaneous Nephrolithotomy in Patients Without Risk Factors[NCT03774940] | 519 participants (Actual) | Interventional | 2005-01-01 | Completed | |||
The Preventive Urinary Tract Infection Role of One Week Solutions of Antimicrobial Application Before Minimally Invasive Upper Tract Lithotomy[NCT02789579] | Early Phase 1 | 150 participants (Anticipated) | Interventional | 2016-09-30 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
To measure and compare the rates of infection following TRUSP in subjects with and without CR-GNB. This measure is number of participants with post-biopsy infection. (NCT01659866)
Timeframe: 30 days post-biopsy
Intervention | participants (Number) |
---|---|
Cipro-susceptible | 6 |
Cipro-resistant | 3 |
8 reviews available for ciprofloxacin and Sepsis
Article | Year |
---|---|
Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Biopsy, Large-Core Needle; Ciproflo | 2018 |
Prevertebral neck abscess with
Topics: Abscess; Ceftriaxone; Ciprofloxacin; Diabetes Mellitus, Type 2; Drainage; Humans; Male; Metronidazol | 2019 |
Is your patient taking the right antimicrobial?
Topics: Adult; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; Causality; Ciprofloxacin | 2008 |
Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model.
Topics: Anaphylaxis; Anti-Bacterial Agents; Ciprofloxacin; Decision Trees; Drug Hypersensitivity; Gram-Negat | 2011 |
Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria; beta-Lactams; Ciprofloxacin; Critical Care; Drug A | 2006 |
Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antitubercular; Breast Neoplasms; Ciprofloxacin; Dr | 1997 |
Hospital-acquired brevundimonas vesicularis septicaemia following open-heart surgery: case report and literature review.
Topics: Adult; Anti-Infective Agents; Aztreonam; Ciprofloxacin; Cross Infection; Female; Humans; Microbial S | 2000 |
Prevention of infection by ciprofloxacin in neutropenia.
Topics: Ciprofloxacin; Erythromycin; Feces; Gram-Negative Bacteria; Humans; Neutropenia; Sepsis; Staphylococ | 1990 |
18 trials available for ciprofloxacin and Sepsis
Article | Year |
---|---|
Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; COVID-19; Critical Illness; Humans; Pandemics; Sepsis; | 2022 |
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; An | 2020 |
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac | 2017 |
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac | 2017 |
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac | 2017 |
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac | 2017 |
Chemoprophylaxis during transrectal prostate needle biopsy: critical analysis through randomized clinical trial.
Topics: Adenocarcinoma; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Large-Core Needle; Bloo | 2018 |
Single-dose versus multiple-dose ciprofloxacin plus metronidazole prophylaxis in transrectal ultrasound-guided biopsy of the prostate: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial | 2014 |
Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Drug Monitoring; Endotoxemia; Escherichia coli; Gastroi | 2017 |
Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate.
Topics: Aged; Aged, 80 and over; Amikacin; Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy, Needle; Ci | 2013 |
Comparison of infection and urosepsis rates of ciprofloxacin and ceftriaxone prophylaxis before percutaneous nephrolithotomy: a prospective and randomised study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ceftriaxone; Ciproflo | 2012 |
Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Cytokines; Female; G | 2004 |
One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Dilatation, Pathologic; Female | 2006 |
Ciprofloxacin treatment in preterm neonates in Bangladesh: lack of effects on growth and development.
Topics: Bangladesh; Child Development; Ciprofloxacin; Female; Follow-Up Studies; Humans; Infant; Infant, New | 2006 |
Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial.
Topics: Abscess; Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Double-Blind Method; Drug Resistan | 1995 |
Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephazolin in the prophylaxis of high-risk patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bile; C | 1998 |
Prevention of sepsis following endoscopic retrograde cholangiopancreatography.
Topics: Administration, Oral; Cefazolin; Cholangiopancreatography, Endoscopic Retrograde; Ciprofloxacin; Dou | 1991 |
Ciprofloxacin versus gentamicin in prophylaxis against bacteremia in transrectal prostate needle biopsy.
Topics: Aged; Biopsy, Needle; Ciprofloxacin; Follow-Up Studies; Gentamicins; Humans; Male; Prostate; Rectum; | 1991 |
Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.
Topics: Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Clavulanic Acids; Drug Combination | 1990 |
Randomized study of intravenous versus sequential intravenous/oral regimen of ciprofloxacin in the treatment of gram-negative septicemia.
Topics: Administration, Oral; Aged; Ciprofloxacin; Drug Administration Schedule; Gram-Negative Bacteria; Hum | 1989 |
Serum levels of ciprofloxacin after single oral doses in patients with septicemia.
Topics: Administration, Oral; Adult; Ciprofloxacin; Half-Life; Humans; Random Allocation; Sepsis; Time Facto | 1989 |
158 other studies available for ciprofloxacin and Sepsis
Article | Year |
---|---|
Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-methylquinolones.
Topics: Animals; Anti-Bacterial Agents; Female; Magnetic Resonance Spectroscopy; Male; Mice; Quinolones; Sep | 1996 |
Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
Topics: Animals; Anti-Bacterial Agents; DNA Topoisomerases, Type II; Drug Discovery; Drug Resistance, Multip | 2018 |
'The Violet Killer'-Successful Treatment of an Infant with Chromobacterium violaceum Sepsis.
Topics: Anti-Bacterial Agents; Chromobacterium; Ciprofloxacin; Gram-Negative Bacterial Infections; Humans; I | 2021 |
A 21-Year Survey of Escherichia coli from Bloodstream Infections (BSI) in a Tertiary Hospital Reveals How Community-Hospital Dynamics of B2 Phylogroup Clones Influence Local BSI Rates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Ciproflo | 2021 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2020.
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Congenital brucellosis associated with subsequent Klebsiella pneumoniae co-infection in a premature neonate: A rare case report.
Topics: Amikacin; Anti-Bacterial Agents; Brucellosis; Ciprofloxacin; Coinfection; Female; Gentamicins; Human | 2022 |
Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cohort Studies; Death, Sudden, Cardia | 2022 |
Intravenous to oral transition of antibiotics for gram-negative bloodstream infection at a University hospital in Thailand: Clinical outcomes and predictors of treatment failure.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Gram-Negative Bacterial Infections; HIV Infections | 2022 |
Aetiology, antimicrobial susceptibility and outcome of children with sepsis, admitted at Muhimbili National Hospital, Dar es Salaam.
Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Anti-Inf | 2022 |
Whole genome sequencing of OXA-232-producing
Topics: Amikacin; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Chromosomes; Ciprof | 2022 |
Proton-mediated burst of dual-drug loaded liposomes for biofilm dispersal and bacterial killing.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Bromelains; Ciprofloxacin; Lipids; Liposomes; Mice; Microb | 2022 |
Differences in the distribution of pathogens and antimicrobial resistance in bloodstream infections in migrants compared with non-migrants in Denmark.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Community-Acquired Infections; Denmark; Drug Resis | 2023 |
Urosepsis and Bacteriuria in Patients Undergoing TRUS-Guided Prostate Biopsy.
Topics: Anti-Bacterial Agents; Bacteriuria; Bangladesh; Biopsy; Ciprofloxacin; Cross-Sectional Studies; Esch | 2023 |
Genomics of Aminoglycoside Resistance in Pseudomonas aeruginosa Bloodstream Infections at a United States Academic Hospital.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Resistance, Bacterial; Genomic | 2023 |
Tailoring Antibiotic Prophylaxis for Ureteroscopic Procedures Based on Local Resistance Profiles May Lead to Reduced Rates of Infections and Urosepsis.
Topics: Administration, Oral; Adult; Aged; Ampicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprof | 2020 |
Highly Sensitive Detection of the Antibiotic Ciprofloxacin by Means of Fiber Enhanced Raman Spectroscopy.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Monitoring; Humans; Sepsis; Spectrum Analysis, Raman | 2019 |
Effect of Augmented Antimicrobial Prophylaxis and Rectal Swab Culture-guided Targeted Prophylaxis on the Risk of Sepsis Following Transrectal Prostate Biopsy.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteriological Techniques; Biopsy; Ciprofloxacin; Ge | 2020 |
Carbapenems versus ciprofloxacin/metronidazole for decreasing complications and hospital stay following complicated acute appendicitis surgery: A prospective cohort in an Ecuadorian population.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Appendectomy; Appendicitis; Carbapenems; | 2020 |
Agricultural Injury-Associated
Topics: Adult; Anti-Bacterial Agents; Bacterial Typing Techniques; Chromobacterium; Ciprofloxacin; Farmers; | 2020 |
Early neonatal sepsis and meningitis caused by Elizabethkingia meningoseptica in Saudi Arabia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; | 2020 |
Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacteremia; Ciprofloxacin; Disease Models, | 2021 |
Severe sepsis from a Ciprofloxacin resistant salmonellosis in a kidney transplant recipient.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Kidney Transplantati | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug | 2017 |
Within-host spatiotemporal dynamics of systemic Salmonella infection during and after antimicrobial treatment.
Topics: Ampicillin; Animal Structures; Animals; Anti-Bacterial Agents; Bacterial Load; Blood; Ciprofloxacin; | 2017 |
Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Doxycycline; D | 2017 |
Prophylactic ciprofloxacin for prostate biopsy: a losing bet?
Topics: Anti-Bacterial Agents; Biopsy; Carbapenems; Ciprofloxacin; Humans; Male; Prostate; Sepsis | 2017 |
Preoperative urine culture is unnecessary in asymptomatic men prior to prostate needle biopsy.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Asymptomatic Diseases; Bacteriuria; Biopsy, Nee | 2018 |
Reduced Risk of Sepsis after Prostate Biopsy Using a Cephalosporin-Fluoroquinolone Antibiotic Regimen and Isopropyl Alcohol Needle Washing.
Topics: 2-Propanol; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Body Mass Index; Ceftriaxon | 2018 |
Re: Combined Therapy with Adipose-Derived Mesenchymal Stem Cells and Ciprofloxacin against Acute Urogenital Organ Damage in Rat Sepsis Syndrome Induced by Intrapelvic Injection of Cecal Bacteria.
Topics: Animals; Bacteria; Ciprofloxacin; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Rat | 2017 |
IgA-dominant extracapillary proliferative glomerulonephritis following Escherichia coli sepsis in a renal transplant recipient.
Topics: Aged; Allografts; Biopsy; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Glomerulonep | 2018 |
Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management.
Topics: Amides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Proteins; | 2018 |
Obstructive urosepsis secondary to ureteric herniation into the sciatic foramen.
Topics: Abdominal Pain; Acute Disease; Aged; Anti-Bacterial Agents; Ciprofloxacin; Female; Hernia; Humans; H | 2018 |
Extended-spectrum β-lactamase in the rectal flora of patients undergoing transrectal prostate biopsy: a study of the prevalence in a major metropolitan hospital.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; beta-Lactamases; Cipr | 2019 |
Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Ciprofl | 2019 |
Topics: Animals; Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Colony Count, Microbial; Disease Models, | 2019 |
Bloodstream infection among adults in Phnom Penh, Cambodia: key pathogens and resistance patterns.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Blood; Camb | 2013 |
Re: Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate: E. O. Kehinde, M. Al-maghrebi, M. Sheikh and J. T. Anim J Urol 2013, 189: 911-915.
Topics: Amikacin; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Endosonography; Humans; Male; Prost | 2013 |
Neonatal meningitis and sepsis by Chryseobacterium indologenes: a rare and resistant bacterium.
Topics: Anti-Bacterial Agents; Chryseobacterium; Ciprofloxacin; Drug Resistance, Bacterial; Female; Flavobac | 2014 |
Reply by authors.
Topics: Amikacin; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Endosonography; Humans; Male; Prost | 2013 |
Reply by authors.
Topics: Amikacin; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Endosonography; Humans; Male; Prost | 2014 |
Re: combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate: O. Kehinde, M. Al-Maghrebi, M. Sheikh and J. T. Anim J Urol 2013; 189: 911–915.
Topics: Amikacin; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Endosonography; Humans; Male; Prost | 2014 |
Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
Topics: Adolescent; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Agents; Child; Child, Preschoo | 2014 |
Cationic nanoemulsions bearing ciprofloxacin surf-plexes enhances its therapeutic efficacy in conditions of E. coli induced peritonitis and sepsis.
Topics: Animals; Anti-Bacterial Agents; Cations; Chitosan; Ciprofloxacin; Deoxycholic Acid; Drug Carriers; E | 2014 |
Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antibiotic Prophylaxis; | 2014 |
In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Toxins; Cefotaxime; Cell Death; Ciprofloxacin; Colony Coun | 2014 |
Prevalence of ciprofloxacin-resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Ciprofloxacin; Drug Resistance, Bacteri | 2015 |
Prophylactic antibiotics reduce sepsis after biopsy of the prostate.
Topics: Aged; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Denmark; Drug Resistance, Bacterial; Hu | 2014 |
Phage-mediated dispersal of biofilm and distribution of bacterial virulence genes is induced by quorum sensing.
Topics: Animals; Biofilms; Caco-2 Cells; Ciprofloxacin; Endocarditis, Bacterial; Enterococcus faecalis; Fema | 2015 |
Comparative Effectiveness of Targeted vs Empirical Antibiotic Prophylaxis to Prevent Sepsis from Transrectal Prostate Biopsy: A Retrospective Analysis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Ciprofloxacin; Escherichia coli; Escherichia | 2015 |
Catheter related line sepsis resulting from Mycobacterium chelonae infection in an immunocompromised host.
Topics: Adult; Catheter-Related Infections; Ciprofloxacin; Clarithromycin; Cross Infection; Drug Therapy, Co | 2015 |
Successful Treatment of Chromobacterium violaceum Sepsis in a South Indian Adult.
Topics: Abscess; Anti-Bacterial Agents; Chromobacterium; Ciprofloxacin; Female; Humans; Imipenem; India; Mel | 2015 |
Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Biopsy; Ceftriaxone; Ciprofloxacin; | 2015 |
Reply by Authors.
Topics: Antibiotic Prophylaxis; Biopsy; Ciprofloxacin; Escherichia coli Infections; Humans; Male; Prostate; | 2016 |
Re: Comparative Effectiveness of Targeted vs Empirical Antibiotic Prophylaxis to Prevent Sepsis from Transrectal Prostate Biopsy: A Retrospective Analysis: M. A. Liss, W. Kim, D. Moskowitz and R. J. Szabo J Urol 2015;194:397-402.
Topics: Antibiotic Prophylaxis; Biopsy; Ciprofloxacin; Escherichia coli Infections; Humans; Male; Prostate; | 2016 |
Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection.
Topics: Anti-Infective Agents, Local; Antibiotic Prophylaxis; Bacterial Infections; Biopsy, Needle; Ciproflo | 2015 |
Septicemia Caused by Neisseria meningitidis With Decreased Ciprofloxacin Susceptibility: The First Case Report in Korea.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ceftriaxone; Ciprofloxacin; Disk Diffusion Antimicrobial | 2016 |
A case report of inhalation anthrax acquired naturally.
Topics: Aged; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Clindamycin; Fatal | 2016 |
Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Ciprofloxacin; Criti | 2016 |
Vibrio vulnificus infection and liver cirrhosis: a potentially lethal combination.
Topics: Adult; Animals; Ciprofloxacin; Debridement; Doxycycline; Early Diagnosis; Humans; Liver Cirrhosis; M | 2016 |
The prevalence of urinary tract infection, or urosepsis following transrectal ultrasound-guided prostate biopsy in a subset of the Saudi population and patterns of susceptibility to flouroquinolones.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Needle; Cipro | 2016 |
Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Chromosomes, Bacterial; Ciprofloxacin; Disease Models, Animal; Esche | 2016 |
Opioid Dependent Malingerer with Self-Induced Sepsis.
Topics: Analgesics, Opioid; Anti-Bacterial Agents; Antifungal Agents; Ciprofloxacin; Echinocandins; Emergenc | 2016 |
Re: Combined Therapy with Adipose-Derived Mesenchymal Stem Cells and Ciprofloxacin against Acute Urogenital Organ Damage in Rat Sepsis Syndrome Induced by Intrapelvic Injection of Cecal Bacteria.
Topics: Adipose Tissue; Adiposity; Animals; Bacteria; Ciprofloxacin; Disease Models, Animal; Humans; Mesench | 2016 |
Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction.
Topics: Aged; Anti-Bacterial Agents; Benzoates; Ciprofloxacin; Deferasirox; DNA, Bacterial; Drug Therapy, Co | 2008 |
[Two cases of Bacillus infection and immunodepression].
Topics: Amoxicillin; Anti-Bacterial Agents; Bacillus; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Clav | 2008 |
Antimicrobial resistance among Escherichia coli strains isolated from healthy and septicemic chickens.
Topics: Animals; Anti-Infective Agents; Bacteremia; Case-Control Studies; Chickens; Ciprofloxacin; Drug Resi | 2007 |
Mycotic abdominal aortic aneurysm due to Streptococcus suis: a case report.
Topics: Aneurysm, Infected; Animals; Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Arthritis, Infectiou | 2010 |
Toxic epidermal necrolysis and agranulocytosis: rare adverse effects of ciprofloxacin.
Topics: Administration, Oral; Adult; Agranulocytosis; Anti-Bacterial Agents; Anti-Infective Agents; Ciproflo | 2009 |
Severe systemic sepsis due to pyogenic liver abscess.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fatal Outcome; Humans; Imipenem; Klebsiella Infections; Klebsi | 2012 |
Ciprofloxacin prevents myelination delay in neonatal rats subjected to E. coli sepsis.
Topics: Animals; Animals, Newborn; Anti-Infective Agents; Ciprofloxacin; Demyelinating Diseases; Escherichia | 2011 |
An investigation on the approach to target lipopolysaccharide through polymeric capped nano-structured formulation for the management of sepsis.
Topics: Animals; Anti-Infective Agents; Chitosan; Ciprofloxacin; Deoxycholic Acid; Drug Compounding; Lipopol | 2011 |
In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Animals; Anti-Infective Agents; Biological Transport, Active; Cell Line; Ce | 2012 |
Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Biopsy, Needle; Ciprofloxacin; Emergencies; E | 2012 |
[Neonatal infection with Stenotrophomonas maltophilia (2 case studies)].
Topics: Amikacin; Anti-Bacterial Agents; Brain Abscess; Chloramphenicol; Ciprofloxacin; Cross Infection; Dru | 2012 |
Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Needle; Chi-Square Distribution; Ciprof | 2012 |
Effect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Administration Routes; Drug Administ | 2012 |
Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections.
Topics: Anti-Bacterial Agents; Antifungal Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Util | 2013 |
Cutaneous abscess leading to sepsis by Aeromonas hydrophila.
Topics: Abscess; Aeromonas hydrophila; Cefepime; Cephalosporins; Ciprofloxacin; Fever; Gram-Negative Bacteri | 2013 |
Factor X inhibitor: a fulminant presentation and fatal course of a rare syndrome in a 59-year-old male.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Ciprofloxac | 2013 |
Systemic exposure, tissue distribution, and disease evolution of a high solubility ciprofloxacin-aluminum complex in a murine model of septicemia induced by salmonella enterica serotype Enteritidis.
Topics: Aluminum; Animals; Ciprofloxacin; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity | 2013 |
The use of ciprofloxacin and fluconazole in Italian neonatal intensive care units: a nationwide survey.
Topics: Anti-Infective Agents; Antifungal Agents; Ciprofloxacin; Drug Utilization; Fluconazole; Health Care | 2013 |
Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
Topics: Acute Disease; Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Progression; | 2002 |
[Epidemiology of septicaemia pathogens].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Austria; Bacteremia; Bacteria; Ciprofloxacin; Drug Res | 2002 |
A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene.
Topics: Anti-Infective Agents; Ciprofloxacin; Critical Illness; Gangrene; Humans; Male; Middle Aged; Sepsis; | 2003 |
Patterns of mutations in target genes in septicemia isolates of Escherichia coli and Klebsiella pneumoniae with resistance or reduced susceptibility to ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; | 2003 |
Extracranial mycotic carotid pseudoaneurysm.
Topics: Aneurysm, False; Aneurysm, Infected; Anti-Infective Agents; Carotid Artery Diseases; Carotid Artery, | 2003 |
Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cecum; Ciprofloxacin; Clindamycin; Colony-For | 2004 |
Isolation of Salmonella enterica serotype choleraesuis resistant to ceftriaxone and ciprofloxacin.
Topics: Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Male; Microbial Se | 2004 |
Chryseobacterium meningosepticum infections in a dialysis unit.
Topics: Chryseobacterium; Ciprofloxacin; Cross Infection; Equipment Contamination; Flavobacteriaceae Infecti | 2004 |
Multiple dose pharmacokinetics of ciprofloxacin in preterm babies.
Topics: Anti-Infective Agents; Birth Weight; Ciprofloxacin; Humans; Infant, Newborn; Infant, Premature; Infa | 2004 |
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cytarabine; Ec | 2004 |
Safety profile of ciprofloxacin used for neonatal septicemia.
Topics: Anti-Infective Agents; Cartilage; Ciprofloxacin; Female; Humans; Infant, Newborn; Male; Sepsis; Ultr | 2004 |
Chromobacterium violaceum septicaemia from north India.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, Preschool; Chromobacter | 2004 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DN | 2005 |
Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Body Fluid Compartments; Ciprofloxac | 2005 |
Effect of combination therapy with ciprofloxacin and azlocillin in intensive care patients with pneumonia and/or sepsis.
Topics: Anti-Bacterial Agents; Azlocillin; Bacteria; Ciprofloxacin; Clinical Trials as Topic; Critical Care; | 1989 |
A rare cause of sepsis in an 18 year old. Lemierre's syndrome with external jugular vein thrombosis.
Topics: Adolescent; Anti-Infective Agents; Body Piercing; Ciprofloxacin; Clindamycin; Diagnosis, Differentia | 2006 |
Anterior surgery with insertion of titanium mesh cage and posterior instrumented fusion performed sequentially on the same day under one anesthesia for septic spondylitis of thoracolumbar spine: is the use of titanium mesh cages safe?
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Internal Fixat | 2006 |
Ceftriaxone-resistant Salmonella septicemia and osteomyelitis in sickle cell disease adults.
Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Ciprofloxacin | 2006 |
One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Nephrostomy, Percutaneous; Preoperative Care; Sensitiv | 2007 |
Budvicia aquatica sepsis in an immunocompromised patient following exposure to the aftermath of Hurricane Katrina.
Topics: Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Disasters; Enterobacteriaceae; Enterobacter | 2007 |
Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
Topics: Animals; Carboxypeptidase B2; Ciprofloxacin; Enterococcus faecalis; Gram-Negative Bacterial Infectio | 2007 |
Salmonella-a new threat to neonates.
Topics: Bangladesh; Ciprofloxacin; Cross-Sectional Studies; Female; Humans; Imipenem; Infant, Newborn; Male; | 2007 |
Optimizing use of ciprofloxacin: a prospective intervention study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Prescriptions; Drug Resis | 2008 |
Endotoxemic pulmonary hypertension is largely mediated by endothelin-induced venous constriction.
Topics: Animals; Ciprofloxacin; Endothelin-1; Female; Hypertension, Pulmonary; Lipopolysaccharides; Lung; Ma | 2008 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Kle | 1995 |
[Sepsis and spondylodiscitis caused by Salmonella enteritidis].
Topics: Ciprofloxacin; Discitis; Drug Administration Schedule; Humans; Male; Middle Aged; Radiography; Salmo | 1993 |
Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis.
Topics: Anti-Infective Agents; Cell Line; Ciprofloxacin; Drug Evaluation, Preclinical; Endothelium, Vascular | 1997 |
The relationship between the use of flucloxacillin, vancomycin, aminoglycosides and ciprofloxacin and the susceptibility patterns of coagulase-negative staphylococci recovered from blood cultures.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Coagul | 1997 |
Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity.
Topics: Animals; Anti-Bacterial Agents; Body Temperature; Cecum; Ciprofloxacin; Clindamycin; Cytokines; Drug | 1998 |
Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group.
Topics: Adult; Animals; Anti-Infective Agents; Ciprofloxacin; Humans; Injections, Intravenous; Metabolic Cle | 1998 |
Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals.
Topics: Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Com | 1998 |
Successful treatment of late-onset infection due to resistant Klebsiella pneumoniae in an extremely low birth weight infant using ciprofloxacin.
Topics: Age of Onset; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Multiple; Drug Therapy, Combina | 1999 |
Successful treatment of an infant with Chromobacterium violaceum sepsis.
Topics: Anti-Bacterial Agents; Chromobacterium; Ciprofloxacin; Female; Gram-Negative Bacterial Infections; H | 2001 |
Aeromonas sobria sepsis in a neutropenic patient.
Topics: Acute Disease; Aeromonas; Aged; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxaci | 2001 |
Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?
Topics: Anti-Infective Agents; Child, Preschool; Ciprofloxacin; Female; Humans; Infant; Injections, Intraven | 2002 |
Antibiotic susceptibility pattern of Salmonella worthington isolated from neonates--a retrospective study.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Chloramphenicol; Ciprofloxacin; | 2002 |
Salmonella, Campylobacter and Shigella in HIV-seropositive patients.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Campylobacter Infections; CD4-Positive T-Lymphoc | 1992 |
Successful treatment of Bacillus cereus infection with ciprofloxacin.
Topics: Adult; Bacillus cereus; Ciprofloxacin; Humans; Male; Pneumonia; Sepsis | 1991 |
Oral antibiotic prophylaxis in patients with hematological diseases.
Topics: Ciprofloxacin; Humans; Norfloxacin; Sepsis; Staphylococcal Infections | 1991 |
Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Erythromycin; Fe | 1991 |
Septicaemia caused by an imported strain of multiply antibiotic resistant Salmonella typhi successfully treated with ciprofloxacin.
Topics: Ciprofloxacin; Drug Resistance, Microbial; Feces; Humans; India; Male; Middle Aged; Recurrence; Salm | 1990 |
Splenic and renal abscesses following Salmonella virchow septicaemia--conservative management with ciprofloxacin.
Topics: Abscess; Adult; Ciprofloxacin; Female; Humans; Kidney Diseases; Salmonella Infections; Sepsis; Splen | 1990 |
Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates.
Topics: Amikacin; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Cross Infection; Enterobacteriaceae; | 1990 |
Reversible leukopenia related to ciprofloxacin therapy.
Topics: Ciprofloxacin; Endocarditis, Bacterial; Female; Heart Valve Prosthesis; Humans; Leukopenia; Middle A | 1990 |
Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin.
Topics: Aged; Ciprofloxacin; Coagulase; Drug Resistance, Microbial; Female; Humans; Immune Tolerance; Leukem | 1990 |
Prevention of bacteremias caused by alpha-hemolytic streptococci by roxithromycin in patients treated with intensive cytotoxic treatment.
Topics: Acute Disease; Adult; Agranulocytosis; Amphotericin B; Antineoplastic Combined Chemotherapy Protocol | 1990 |
Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Ciprofloxacin; Humans; Male; Postoperative Compli | 1986 |
[Ciprofloxacin: a solution for recurrent bacteremia caused by Salmonella non typhi in acquired immunodeficiency syndrome?].
Topics: Acquired Immunodeficiency Syndrome; Ciprofloxacin; Humans; Male; Middle Aged; Recurrence; Salmonella | 1989 |
Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit.
Topics: Cancer Care Facilities; Ciprofloxacin; Coagulase; Cross Infection; Disease Outbreaks; Drug Resistanc | 1989 |
Successful treatment with ciprofloxacin of multiresistant salmonella arthritis in a renal transplant recipient.
Topics: Arthritis, Infectious; Ciprofloxacin; Drug Resistance, Microbial; Female; Hip Joint; Humans; Opportu | 1989 |
Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Drug Administration Schedule; Female; Ge | 1989 |
Ciprofloxacin in patients with bacteremic infections. The Spanish Group for the Study of Ciprofloxacin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Ciprofloxacin; Female; H | 1989 |
Intravenous and oral ciprofloxacin treatment of 52 infections.
Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Female; Humans; Infusions, Intravenous; M | 1989 |
Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin.
Topics: Adult; Aged; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; | 1989 |
Ciprofloxacin in neonatal Enterobacter cloacae septicaemia.
Topics: Ciprofloxacin; Enterobacter; Enterobacteriaceae Infections; Humans; Infant, Newborn; Infant, Prematu | 1989 |
Bacteraemia caused by Stomatococcus mucilaginosus in a granulocytopenic patient with acute lymphocytic leukaemia.
Topics: Adult; Agranulocytosis; Amsacrine; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Proto | 1989 |
Ciprofloxacin for Salmonella bacteremia in the acquired immunodeficiency syndrome (AIDS).
Topics: Acquired Immunodeficiency Syndrome; Adult; Ciprofloxacin; Humans; Male; Middle Aged; Recurrence; Sal | 1989 |
Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Female; Imipenem; | 1989 |
[A case report of septicemia caused by methicillin cephem resistant Staphylococcus aureus (MRSA)].
Topics: Ciprofloxacin; Female; Humans; Methicillin; Middle Aged; Penicillin Resistance; Sepsis; Staphylococc | 1989 |
Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia.
Topics: Ciprofloxacin; Humans; Male; Middle Aged; Pneumococcal Infections; Pneumonia, Pneumococcal; Sepsis | 1989 |
Open, prospective study of the clinical efficacy of ciprofloxacin.
Topics: Adolescent; Adult; Aged; Arthritis; Bacterial Infections; Ciprofloxacin; Female; Gastrointestinal Di | 1985 |
Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Drug Resistance, Microbial; Hu | 1985 |
Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a splenectomized and immunosuppressed patient.
Topics: Adult; Ciprofloxacin; Humans; Immunosuppression Therapy; Male; Salmonella Infections; Salmonella typ | 1988 |
Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin.
Topics: Adolescent; Aged; Agranulocytosis; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; | 1987 |
Enterococcal superinfection in patients treated with ciprofloxacin.
Topics: Adult; Aged; Ciprofloxacin; Enterococcus faecalis; Humans; Kidney Failure, Chronic; Male; Pseudomona | 1988 |
Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Drug Administration Schedule; E | 1988 |
Comparative efficacy of ciprofloxacin, ceftazidime and gentamicin, given alone or in combination, in a model of experimental septicemia due to Klebsiella pneumoniae in neutropenic mice.
Topics: Agranulocytosis; Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combinat | 1988 |
Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.
Topics: Animals; Ceftazidime; Ciprofloxacin; Drug Administration Schedule; Female; Klebsiella Infections; Kl | 1987 |
Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro.
Topics: Animals; Ceftazidime; Ciprofloxacin; Drug Administration Schedule; Klebsiella Infections; Klebsiella | 1987 |
Ciprofloxacin: initial evaluation in immunocompromised patients.
Topics: Antineoplastic Agents; Bacterial Infections; Bone Marrow Transplantation; Ciprofloxacin; Humans; Imm | 1987 |
In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Fluoroquinolones; Gram-Negative | 1987 |
Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients.
Topics: Adult; Aged; Agranulocytosis; Bacterial Infections; Ciprofloxacin; Female; Fever; Half-Life; Humans; | 1986 |
Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a patient with acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Ciprofloxacin; Humans; Male; Recurrence; Salmonella Infec | 1986 |
Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
Topics: Animals; Ciprofloxacin; Drug Evaluation, Preclinical; Endocarditis, Bacterial; Kinetics; Methicillin | 1987 |
Dosage of intravenous ciprofloxacin.
Topics: Acute Kidney Injury; Adult; Ciprofloxacin; Humans; Injections, Intravenous; Male; Pseudomonas Infect | 1987 |
Comparative in vitro activity of ciprofloxacin and other antimicrobial agents against aminoglycoside-resistant gram-negative rods and microorganisms isolated from patients with bacteremia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Gram-Negative Bac | 1986 |
Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Clofazimine; Cyc | 1987 |